A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activation Mutations.

Trial Profile

A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activation Mutations.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2017 Planned End Date changed from 1 Sep 2015 to 1 Sep 2020.
    • 24 Aug 2017 Planned primary completion date changed from 1 Jun 2014 to 1 Sep 2019.
    • 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top